Related Experiment Video
Updated: May 21, 2025

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
Published on: July 18, 2013
Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response
Mary Helen Barcellos-Hoff1, Sue S Yom2
1Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA. maryhelen.barcellos-hoff@ucsf.edu.
Abstract:
The transforming growth factor-β (TGFβ) paradox refers to the well-established role of TGFβ in suppressing cancer in healthy tissues yet promoting malignancy in established cancers. Although this positioned TGFβ inhibitors as a potential therapeutic strategy for malignancy, therapuetic blockade has failed in multiple clinical trials. The general lack of selection principles for defining which patients would most benefit from the addition of a TGFβ inhibitor has probably hindered its deployment. Here, we highlight the therapeutic potential in TGFβ regulation of DNA repair using human papillomavirus (HPV)-driven head and neck squamous cell carcinoma (HNSCC) as an illustrative example. HPV inhibits TGFβ signalling, which in turn reduces DNA damage repair, ultimately conferring sensitivity to cancer treatments and thus contributing to the favourable prognosis of HPV-positive HNSCC. Here, we review the DNA repair deficit caused by a loss of TGFβ signalling and how this could be targeted to induce synthetic lethality. Moreover, we explore its role in predicting response to immune checkpoint inhibitors and the potential of biomarkers to select which patients with cancer could ultimately benefit from TGFβ inhibition.
Insights
Transforming growth factor-β (TGFβ) paradoxically suppresses healthy tissues but promotes established cancers. Targeting TGFβ
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The transforming growth factor-β (TGFβ) paradox describes its dual role in cancer: suppression in healthy tissues and promotion in established malignancies.
- TGFβ inhibitors have shown limited success in clinical trials due to a lack of patient selection criteria.
- Understanding TGFβ's role in DNA repair is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To explore the therapeutic potential of targeting TGFβ regulation of DNA repair in human papillomavirus (HPV)-driven head and neck squamous cell carcinoma (HNSCC).
- To review how loss of TGFβ signaling impacts DNA repair and its potential for synthetic lethality induction.
- To investigate TGFβ's role in predicting response to immune checkpoint inhibitors and the utility of biomarkers for patient selection.
Main Methods:
- Review of existing literature on TGFβ signaling, DNA repair mechanisms, and HPV-driven HNSCC.
- Analysis of the interplay between HPV, TGFβ inhibition, and DNA damage repair pathways.
- Exploration of synthetic lethality strategies targeting DNA repair deficits.
- Assessment of TGFβ's predictive value for immune checkpoint inhibitor response.
Main Results:
- HPV inhibits TGFβ signaling, leading to reduced DNA damage repair in HNSCC.
- This DNA repair deficit confers sensitivity to cancer treatments and contributes to favorable prognosis in HPV-positive HNSCC.
- Targeting the DNA repair deficit caused by TGFβ loss offers a potential synthetic lethality strategy.
- TGFβ pathway status may predict response to immune checkpoint inhibitors.
Conclusions:
- TGFβ's complex role in cancer necessitates refined therapeutic strategies.
- Targeting DNA repair deficits induced by TGFβ pathway alterations presents a promising approach for specific cancer types.
- Biomarkers are essential for identifying patients who would benefit from TGFβ-targeted therapies, including immune checkpoint inhibitors.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
Related Concept Videos
TGF - β Signaling Pathway
DNA Damage can Stall the Cell Cycle
Proofreading
DNA Helicases
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Restarting Stalled Replication Forks